phentermine chest pains

tramadol ultram 50mg

" The landmark ATHENA trial evaluated the efficacy and safety of Multaq in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% were in NYHA class I-III with stable heart failure)., Professor of Medicine & Director, Division of Cardiology, McMaster University, Hamilton, Canada, and co-principal investigator in the ATHENA study. In contrast, in ATHENA, all patients had a history of AF/AFL, and 71% of patients had no heart failure, 25% were NYHA class I or II, and only 4% were class III. phentermine chest pains Important Safety Information Multaq is contraindicated in patients with NYHA Class IV heart failure or NYHA Class II-III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. phentermine chest pains The mPACT(TM) Partnership was developed to assist healthcare professionals (HCPs) with the identification of appropriate patients and to ensure the safe use of Multaq while minimizing risk. meridia contents

PARIS, July 02, 2009 /PRNewswire-FirstCall/ --Sanofi-aventis announced today that the U. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Viehbacher, Chief Executive Officer of sanofi-aventis." The landmark ATHENA trial evaluated the efficacy and safety of Multaq in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% were in NYHA class I-III with stable heart failure).1mg/dL following Multaq treatment initiation. phentermine chest pains Multaq is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted.pdf About Atrial Fibrillation/Atrial Flutter Atrial fibrillation is the leading cause of hospitalization for arrhythmia in the U. phentermine chest pains Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease." Multaq is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. soma tablets

"The FDA approval of Multaq is an important milestone in the management of atrial fibrillation or atrial flutter that demonstrates the commitment of sanofi-aventis to provide patients and physicians with important new medicines in therapeutic areas with significant healthcare needs," said Christopher A. To ensure the use of Multaq in the appropriate patient population, sanofi-aventis U. "We are pleased that the FDA has granted approval of Multaq for patients in a therapeutic area that has seen few new treatment options in the last twenty years," said Marc Cluzel, MD, Senior Vice President, Research and Development, sanofi-aventis. Hospitalization associated with AF has increased dramatically (two-to-three fold) in recent years in the U. phentermine chest pains Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. Such patients should not be given dronedarone. phentermine chest pains pdf About Atrial Fibrillation/Atrial Flutter Atrial fibrillation is the leading cause of hospitalization for arrhythmia in the U.